期刊文献+

促红细胞生成素对难愈创面患者康复的影响 被引量:7

The effects of erythropoietin on impaired wound healing
下载PDF
导出
摘要 目的 探讨促红细胞生成素(erythropoietin,EPO)水平对难愈创面康复的影响.方法 收集2011年9月~2012年12月治疗的60例超过两个月创面未愈合的患者,按随机方法分为EPO治疗组30例和常规治疗组(对照组)30例.治疗8周后比较两组患者创面肉芽组织和上皮的生长情况,并分别采用ELISA技术检测血清中EPO和血管内皮生长因子(VEGF)水平.结果 与对照组同期比较,EPO治疗2~8周患者创面肉芽组织生长情况和上皮化程度均显著增加(P<0.05),同时血清EPO含量和VEGF水平均显著高于对照组(P<0.05).结论 促红细胞生成素可促进难愈创面肉芽组织的生长、血管的再生和患者创面的愈合. Objective To investigate the effect of erythropoietin (EPO) on impaired wound healing.Methods 60 patients with impaired wound more than two months were randomly divided into EPO treatment group (n=30) and rou tine treatment group (control group,n=30).The growth of wound granulation tissue and epithelial in both group were measured and compared 8 weeks after treatment.The level of EPO and vascular endothelial growth factor (VEGF) in serum were detected by enzyme-linked immuno sorbent assay.Results Compared with control group,the growth of wound granulation tissue and epithelial of patients in EPO treatment group increased significantly in the same period (P〈0.05),meanwhile levels of EPO and VEGF in serum were significantly higher than that of control group (P〈0.05).Conclusion Erythropoietin can promote the growth of wound granulation tissue,regeneration of blood vessels and promote wound healing.
出处 《西部医学》 2014年第10期1354-1356,共3页 Medical Journal of West China
关键词 促红细胞生成素 难愈创面 愈合 血管内皮生长因子 Erythropoietin Impaired wound Healing Vascular Endothelial growth factor
  • 相关文献

参考文献12

  • 1E.Bovill,P.E.Banwell,L.Teot,et al.Topical negative pressure wound therapy:a review of its role and guidelines for its use in the management of acute wounds[J].Int Wound J,2008,5(4):511-529.
  • 2N.Itoh and D.M.Ornitz.Fibroblast growth factors:from molecular evolution to roles in development,metabolism and disease[J].J Biochem,2011,149(2):121-130.
  • 3R.A.Clark,K.Ghosh,and M.G.Tonnesen.Tissue engineering for cutaneous wounds[J].J Invest Dermatol,2007,127(5):1018-1029.
  • 4牟斌,王成刚,李宗瑜,朱应来,阚侃,张海霞,郭凤春.持续负压封闭引流在深度难愈创面上的应用与探讨[J].创伤外科杂志,2010,12(4):371-371. 被引量:10
  • 5M.Abe,Y.Yokoyama,and O.Ishikawa.A possible mechanism of basic fibroblast growth factor-promoted scarless wound healing:the induction of myofibroblast apoptosis[J].Eur J Dermatol,2012,22(1):46-53.
  • 6张兆新,吕磊,刘小龙,刘利华,张亮,纪东亮,查天建.重组人表皮生长因子凝胶在慢性难愈性溃疡创面中的应用研究[J].中华临床医师杂志(电子版),2011,5(8):2186-2190. 被引量:20
  • 7W.Jelkmann and K.Wagner.Beneficial and ominous aspects of the pleiotropic action of erythropoietin[J].Ann Hematol,2004,83(11):673-686.
  • 8K.Le Minh,K.Klemm,K.Abshagen,et al.Attenuation of inflammation and apoptosis by pre-and posttreatment of darbepoetin-alpha in acute liver failure of mice[J].Am J Pathol,2007,170(6):1954-1963.
  • 9R.Shurtz-Swirski,B.Kristal,S.M.Shasha,et al.Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in continuous ambulatory dialysis patients[J].Nephron,2002,91(4):759-761.
  • 10M.Nairz,T.Sonnweber,A.Schroll,et al.The pleiotropic effects of erythropoietin in infection and inflammation[J].Microbes Infect,2012,14(3):238-246.

二级参考文献4

共引文献28

同被引文献40

  • 1田同荣.恶性肿瘤患者化疗引起口腔黏膜炎的危险因素分析[J].中国肿瘤临床与康复,2007,14(2):186-189. 被引量:20
  • 2Rizzo JD,M Brouwers,P. Hurley,etal. American Society of He- matology and the American Society of Clinical Oncology Practice Guideline Update Committee[J]. American Society of Hematol- ogy/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer [J]. Blood, 2010, 116: 4045-4059.
  • 3Mammis A, McIntosh TK, Maniker AH,et al. Erythropoietin as a neuroprotective agent in traumatic brain injury [J]. Surg Neurol, 2009, 71(5): 527-531.
  • 4Yoshmiura A, Zmimers T, Neumann D, et al. Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish processing, ligand binding, and activation of the receptor [J]. Biol Chem, 1992, 267(16): 11619-11625.
  • 5Szenajch J, G. Wcislo JY, Jeong C,et al. The role of erythro- poietin and its receptor in growth, survival and therapeutic re- sponse of human tumor cells From clinic to bench- a critical re- view [J]. Biochim. Biophys, 2010, 1806: 82-86.
  • 6Wojchowski DM,P. Sathyanarayana, and A. Dev,et al. Eryth- ropoietin receptor response circuits [J]. Curt. Opin. Hematol, 2010, 17(3): 169-176.
  • 7Gan Y. Mutant erythropoietin without erythropoietic activity is neuroprotective against isehemic brain injury [J]. Stroke, 2012, 43(11): p. 3071-3077.
  • 8Leist M, Ghezzi P,Grasso G,etal. Derivatives of erythropoietin that are tissue proteetive but not erythropoietic [J]. Science, 2004, 305(5681): 239-242.
  • 9Erbayraktar S,Grasso G,Sfacteria A,etal. Asialoerythropoietin is a nonerythropoietic cytokine withbroad neuroprotective activi- ty in vivo[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(11) : 6741-6746.
  • 10Bemuzzi G, Petraglia P, Pedrini M F, et al.Use of platelet-rich plasma in the care of sports injuries : our experience with ultrasoundguided injection[J].Trasfusione del sangue, 2014, 12 ( 1 ) : s229-234.

引证文献7

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部